Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Méhats, Céline ^a,b,e   Franco Montoya, Marie Laure ^c,e   Boucherat, Olivier ^c,e   Lopez, Emmanuel ^a,b,e   Schmitz, Thomas ^a,b,e   Zana, Elodie ^a,e   Evain Brion, Danièle ^a,b,e   Bourbon, Jacques ^c,d,e   Delacourt, Christophe ^c,d,e   Jarreau, Pierre Henri ^a,b,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM U955   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e PremUP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PHOSPHODIESTERASE IV; ROLIPRAM; PHOSPHODIESTERASE INHIBITOR;

AMBIENT AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; HYPEROXIA; LEUKOCYTE MIGRATION; LOW DRUG DOSE; LUNG ALVEOLUS CELL; LUNG DEVELOPMENT; LUNG INJURY; LUNG LAVAGE; NEWBORN; NEWBORN MORTALITY; NONHUMAN; OXYGEN SATURATION; PNEUMONIA; RAT; RESPIRATORY TRACT PARAMETERS; WEIGHT GAIN; ANIMAL; DRUG ANTAGONISM; GROWTH, DEVELOPMENT AND AGING; INFLAMMATION; LUNG ALVEOLUS; MORTALITY; PATHOLOGY;

RATTUS;

ANIMALS; ANIMALS, NEWBORN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HYPEROXIA; INFLAMMATION; LUNG INJURY; PHOSPHODIESTERASE INHIBITORS; PULMONARY ALVEOLI; RATS; ROLIPRAM; WEIGHT GAIN;

EID: 55649121816     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003445     Document Type: Article

References (51)

1. Bourbon J, Boucherat O, Chailley-Heu B, Delacourt C (2005) Control mechanisms of lung alveolar development and their disorders in bronchopulmonary dysplasia. Pediatr Res 57: 38R-46R.
2. Kinsella JP, Greenongh A, Abman SH (2006) Bronchopulmonary dysplasia. Lancet 367: 1421-1431.
3. Baraldi E, Filippone M (2007) Chronic lung disease after premature birth. N Engl J Med 357: 1946-1955.
4. Kallapur SG, Jobe AH (2006) Contribution of inflammation to lung injury and development. Arch Dis Child Fetal Neonatal Ed 91: F132-135.
5. Yoon BH, Romero R, Jun JK, Park KH, Park JD, et al. (1997) Amniotic fluid cytokines (interleukin-6, tumor ttecrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 177: 825-830.
6. Zanardo V, Savio V, Giacomin C, Rinaldi A, Marzari F, et al. (2002) Relationship between neonatal leukemoid reaction and bronchopulmonary dysplasia in low-birth-weight infants: a cross-sectional study. Am J Perinatol 19: 379-386.
7. Hsiao R, Omar SA (2005) Outcome of extremely low birth weight infants with leukemoid reaction. Pediatrics 116: e43-51.
8. Merritt TA, Cochrane CG, Holcomb K, Bohl B, Hallman M, et al. (1983) Elastasc and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest 72: 656-666.
9. Auten RL Jr, Mason SN, Tanaka DT, Welty-Wolf K, Whorton MH (2001) Anti-neutrophil chemokine preserves alveolar development in hyperoxia-exposed newborn rats. Am J Physiol Lung Cell Mol Physiol 281: L336-344.
10. Torphy TJ (1998) Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157: 351-370.
11. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
12. Giembycz MA (2006) An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol 62: 138-152.
13. Spinal D (2003) Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63: 2575-2594.
14. Burri PH, Dbaly J, Weibel ER (1974) The postnatal growth of the rat lung. I. Morphometry. Anat Rec 178: 711-730.
15. de Visser YP, Walther FJ, Laghmani EH, van Wijngaarden S, Nieuwland K, et al. (2007) Phosphodiesterase 4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur Respir J.
16. Tang HF, Song YH, Chen JC, Chen JQ, Wang P (2005) Upregulation of phosphodiesterase-4 in the lung of allergic rats. Am J Respir Crit Care Med 171: 823-828.
17. Lopez E, Boucherat O, Franco-Montoya ML, Bourbon JR, Delacourt C, et al. (2006) Nitric oxide donor restores lung growth factor and receptor expression in hyperoxia-exposed rat pups. Am J Respir Cell Mol Biol 34: 738-745.
18. Deng H, Mason SN, Auten RL Jr (2000) Lung inflammation in hyperoxia can be prevented by antichemokine treatment in newborn rats. Am J Respir Crit Care Med 162: 2316-2323.
19. ter Horst SA, Wagenaar GT, de Boer E, van Gastelen MA, Meijers JC, et al. (2004) Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol 97: 2014-2019.
20. Naureckas ET, Factor P, Benjaminov O, Hoffer E, Sriram V, et al. (1994) Pentoxifylline does not protect against hyperoxic lung injury in rats. Eur Respir J 7: 1397-1402.
21. Schwabe U, Miyake M, Ohga Y, Daly JW (1976) 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′,5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol 12: 900-910.
22. Nielson CP, Vestal RE, Sturm RJ, Heaslip R (1990) Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 86: 801-808.
23. Schudt C, Winder S, Forderkunz S, Hatzelmann A, Ullrich V (1991) Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol 344: 682-690.
24. Spoto G, Di Giulio C, Contento A, Di Stilio M (1998) Hypoxic and hyperoxic effect on blood phosphodiesterase activity in young and old rats. Life Sci 63: PL349-353.
25. Iona S, Cuomo M, Bushnik T, Naro F, Sette C, et al. (1998) Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol Pharmacol 53: 23-32.
26. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM (1999) Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 56: 170-174.
27. Saugstad OD (2003) Bronchopulmonary dysplasia-oxidative stress and antioxidants. Semin Neonatol 8: 39-49.
28. Wagenaar GT, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, et al. (2004) Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 36: 782-801.
29. Vozzelli MA, Mason SN, Whorton MH, Auten RL Jr (2004) Antimacrophage chemokine treatment prevents neutrophil and macrophage influx in hyperoxia-exposed newborn rat lung. Am J Physiol Lung Cell Mol Physiol 286: L488-493.
30. Jin SL, Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 99: 7628-7633.
31. Denhardt DT, Giachelli CM, Rittling SR (2001) Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41: 723-749.
32. Boucherat O, Franco-Montoya ML, Thibault C, Incitti R, Chailley-Heu B, et al. (2007) Gene expression profiling in lung fibroblasts reveals new players in alveolarization. Physiol Genomics 32: 128-141.
33. Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, et al. (2005) Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2: e251.
34. Boswell-Smith V, Cazzola M, Page CP (2006) Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 117: 1237-1243.
35. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, et al. (1995) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273: 1396-1402.
36. Larson JL, Pino MV, Geiger LE, Simeone CR (1996) The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 78: 44-49.
37. Dagues N, Pawlowski V, Sobry C, Hanton G, Borde F, et al. (2007) Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteirrase 1, a potential predictive biomarker. Toxicol Sci 100: 238-247.
38. Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, Conti M (1999) Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci U S A 96: 11998-12003.
39. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, et al. (2006) Caffeine therapy for apnea of prematurity. N Engl J Med 354: 2112-2121.
40. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, et al. (2007) Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 357: 1893-1902.
41. Massaro D, Teich N, Maxwell S, Massaro GD, Whitney P (1985) Postnatal development of alveoli. Regulation and evidence for a critical period in rats. J Clin Invest 76: 1297-1305.
42. Massaro D, Alexander E, Reiland K, Hoffman EP, Massaro GD, et al. (2007) Rapid onset of gene expression in lung, supportive of formation of alveolar septa, induced by refeeding mice after calorie restriction. Am J Physiol Lung Cell Mol Physiol 292: L1313-1326.
43. Thompson WJ, Appleman MM (1971) Characterization of cyclic nucleotide phosphodiesterases of rat tissues. J Biol Chem 246: 3145-3150.
44. Schmitz T, Souil E, Herve R, Nicco C, Batteux F, et al. (2007) PDE4 inhibition prevents preterm delivery induced by an intrauterine inflammation. J Immunol 178: 1115-1121.
45. Oger S, Mehats C, Dallot E, Ferre F, Leroy MJ (2002) Interleukin-1beta induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E2- and cyclic adenosine 3′,5′-monophosphate-dependent pathway. J Clin Endocrinol Metab 87: 5524-5531.
46. Huston E, Pooley L, Julien P, Scotland G, McPhee I, et al. (1996) The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271: 31334-31344.
47. Waszak P, Franco-Montoya ML, Jacob MP, Deprez I, Levame M, et al. (2002) Effect of intratracheal adenoviral vector administration on lung development in newborn rats. Hum Gene Ther 13: 1873-1885.
48. Weibel ER, Cruz-Orive LM (1997) Morphometric methods, In: Crystal RG, West JB, Weibel ER, Barnes PJ, eds. The lung: scientific foundations. Philadelphia, PA: Lippincott-Raven. pp 333-344.
49. Cooney TP, Thurlbeck WM (1982) The radial alveolar count method of Emery and Mithal: a reappraisal 2-intrauterine and early postnatal lung growth. Thorax 37: 580-583.
50. Cooney TP, Thurlbeck WM (1982) The radial alveolar count method of Emery and Mithal: a reappraisal 1-postnatal lung growth. Thorax 37: 572-579.
51. Zeltner TB, Caduff JH, Gehr P, Pfenninger J, Burri PH (1987) The postnatal development and growth of the human lung. I. Morphometry. Respir Physiol 67: 247-267.